Sarepta Therapeutics, Inc. announced on July 21, 2025, that the FDA has placed a clinical hold on its gene therapy trials for limb girdle muscular dystrophy (LGMD), including product candidates SRP-9003, SRP-9004, SRP-6004, and SRP-9005. The company also indicated that the platform technology designation for AAVrh74 was revoked on the same date.